Healthcare
Galapagos N.V.(GLPG)
Live Price
Offline$28.30
-0.25% today
1Y Change
+4.69%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $1.59B
- Revenue Growth
- +303.5%
- EPS Growth
- +333.0%
- Dividend Yield
- 0.0%
Coverage: 251 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Galapagos N.V. (GLPG) is a Healthcare stock with a market cap of $1.59B and listed on NASDAQ. The stock last traded around $28.30 and up 4.7% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +303.5%, EPS growth of +333.0%, a dividend yield of 0.0%. What stands out right now is revenue +303.5%, EPS +333.0%, free cash flow +49.7% with operating margin 43.6% and ROIC 14.9%. Valuation is more restrained than many high-expectation growth names at P/E 5.0 and price/sales 1.4. Stock Foundry combines GLPG price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+303.5% vs +7.6% peer median
Operating Margin
Above sector median
+43.6% vs +19.4% peer median
P/E
Below sector median
5.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on May 6, 2026 with an EPS surprise of +119.7% and a revenue surprise of -20.4%.
The operating story is still moving forward
Revenue is running at +303.5% and EPS at +333.0%, with operating margin around 43.6%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 10, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.1% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | +119.7% | -3.7% | -2.3% | -2.4% |
2026 Feb 23, 2026 | +1538.0% | +1.4% | +0.6% | -5.8% |
2025 Nov 5, 2025 | -1696.3% | +4.4% | +8.1% | +6.3% |
Benchmark Edge
GLPG vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GLPG
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GLPG Max Drawdown
-29.27%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GLPG and SPY.
Company Overview
Galapagos N.V.
NASDAQ Global Select
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.ร r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
- Leadership
- Henry Gosebruch
- IPO Date
- Feb 27, 2012
- Employees
- 704
- Street Address
- Generaal De Wittelaan L11 A3
- Mailing
- Mechelen, 2800
- Region
- Mechelen, BE
- Reporting Currency
- USD
- Investor Line
- 32 1 534 29 00
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 5.0
- EV/EBITDA
- 3.4
- Price/Sales
- 1.4
- Price/Book
- 0.5
Growth
- Revenue
- +303.5%
- EPS
- +333.0%
- Free Cash Flow
- +49.7%
Profitability
- Gross Margin
- 97.3%
- Operating Margin
- 43.6%
- Net Margin
- 28.9%
- ROE
- 11.2%
- ROIC
- 14.9%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 20.15
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.